You may be eligible if you have commercial insurance and live outside Massachusetts, Michigan, Minnesota, and Rhode Island. Complete the form above and we’ll confirm your eligibility.
Try the MiniMed Flex system at no cost†
Experience the difference that MiniMed automation can make with our Pump Evaluation Program.
Your evaluation includes everything but the insulin
1 MiniMed FlexTM pump
Automated insulin delivery in a small rechargable pump.
30 days of ExtendedTM infusion sets and reservoirs
A 7-day infusion set with a reservoir that holds up to 300 units.
30 days of CGM sensors
Choose between the 15-day Instinct sensor, made by Abbott, or the Simplera SyncTM sensor for once-a-week changes.
Personalized training
We'll help you learn the system and get started.
Frequently asked questions
Can I participate in the MiniMed Flex Patient Evaluation Program?
Can I participate in the MiniMed Flex Patient Evaluation Program?
What do need to participate?
What do need to participate?
Once we confirm you’re eligible, we’ll guide you through the next steps. You’ll need to sign a program agreement, and we’ll take care of getting the prescription from your healthcare professional.
I already use a MiniMed pump. Can I still participate?
I already use a MiniMed pump. Can I still participate?
Maybe. If you haven’t previously tried or purchased MiniMed Flex, you may be eligible. Complete the form above and we’ll check for you.
Footnotes
† Terms and conditions apply
‡ Refers to SmartGuardTM feature. Individual results may vary.
§ Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
◊ Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
¶ Overnight period: 12:00 AM- 6:00 AM. Number of users with ≥10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time.
References
- Arrieta A, et al. Diabetes Obes Metab. 2022;10.1111/dom.14714 .
- McVean JJF, Niu F, Liu M, et al. Automated insulin delivery with the MiniMed™ 780G system reduces burden by improving sleep and glycaemic control overnight. Diabetes Obes Metab. Published online January 8, 2026. doi:10.1111/dom.70380
Program Terms and Conditions:
- You are eligible to participate in this MiniMed Flex System Patient Evaluation Program one time only and must not have used the MiniMed Flex system before.
- To participate, you must submit a signed copy of this agreement and MiniMed must have a valid prescription from your healthcare professional. Other restrictions may apply.
- You are not eligible to participate if you have commercial insurance and reside in Massachusetts, Michigan, Rhode Island and Minnesota and/or you are enrolled in any federal, state or government-funded healthcare programs. You are not eligible to participate if you use Kaiser Permanente health plan.
- With this program, you will receive the MiniMed Flex system, including one (1) MiniMed Flex insulin pump and a 30-day supply of compatible CGM sensors, infusion sets and reservoirs. You agree not to alter the products received through this program in any manner unless pre-approved in writing by MiniMed.
- You agree not to use the MiniMed Flex system until appropriate training has been received from a MiniMed professional. Training is essential to ensure the safe use of the system.
- You agree to return the MiniMed Flex insulin pump to MiniMed within ninety (90) days after completion of the evaluation period.
- At any time during the evaluation period, you may initiate the purchase of the MiniMed Flex system by connecting with your MiniMed Sales Representative. If you choose to do so, you will receive new products with your purchase and need to return the evaluation products on or before the end of the evaluation period to MiniMed.
- You agree to utilize the MiniMed Flex system evaluation products in a manner consistent with the Instructions for Use (IFU). The evaluation products are not intended to diagnose, treat, cure, or prevent any disease.
- The products provided as part of the Patient Evaluation Program are non-transferable and are for use by the program participant only. The products cannot be used by another patient, another healthcare professional, or any other individuals, including but not limited to those individuals with diabetes.
- You agree not to sell or submit the evaluation products, nor the services associated with the products during the evaluation, for third-party reimbursement.
- You acknowledge that you have not received, will not receive, and should not expect to receive any compensation from MiniMed or any of its affiliates for your participation in this program.
- Pricing, terms and conditions are subject to change at any time and without notice.
Important Safety Information: MiniMed FlexTM system with SmartGuardTM technology with Simplera SyncTM sensor and Instinct sensor
The MiniMed FlexTM system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin.
The MiniMed FlexTM system includes SmartGuardTM technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera SyncTM sensor and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.
WARNING: Do not use the SmartGuardTM feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuardTM feature.
WARNING: Do not use the MiniMedTM Flex system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMedTM Flex system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuardTM feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed FlexTM system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including user guides and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, see https://link.minimed.com/Risks.
©2026 Medtronic MiniMed, Inc. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2026 Abbott. TM*Third–party brands are trademarks of their respective owners.